Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
AU Stock MarketDetailed Quotes
Clinuvel Pharmaceuticals Ltd (CUV)
- 9.470
- -0.070-0.73%
20min DelayMarket Closed May 15 16:00 AET
477.55MMarket Cap13.19P/E (Static)
9.600High9.400Low48.83KVolume9.430Open9.540Prev Close462.45KTurnover13.93352wk High0.12%Turnover Ratio50.43MShares8.57052wk Low0.644EPS TTM395.76MFloat Cap45.205Historical High13.19P/E (Static)41.79MShs Float0.172Historical Low0.718EPS LYR2.10%Range %0.05Dividend TTM1.92P/B1Lot Size0.53%Div Yield TTM
Clinuvel Pharmaceuticals Ltd (CUV) Cash Flow
Quarterly+Annual
YOY
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | (FY)Jun 30, 2021 | (FY)Jun 30, 2020 | (FY)Jun 30, 2019 | (FY)Jun 30, 2018 | (FY)Jun 30, 2017 | (FY)Jun 30, 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (direct method) | ||||||||||
| Cash income from operating activities | 10.93%93.82M | 12.92%84.57M | 12.43%74.9M | 71.59%66.62M | 32.01%38.82M | -8.73%29.41M | 35.62%32.22M | 28.34%23.76M | 407.41%18.51M | 43.35%3.65M |
| Revenue from customers | 11.63%93.79M | 12.21%84.02M | 12.77%74.88M | 71.47%66.4M | 32.22%38.72M | -9.10%29.29M | 35.92%32.22M | 32.25%23.71M | 391.29%17.92M | 43.35%3.65M |
| Income from government grants | -92.98%24.18K | 1,464.79%344.39K | -89.87%22.01K | --217.26K | ---- | ---- | ---- | --53.07K | ---- | ---- |
| Other cash income from operating activities | -100.00%2 | --208.59K | ---- | ---- | -18.25%99.36K | --121.54K | ---- | ---- | --588.02K | ---- |
| Cash paid | -11.82%-44.45M | -19.62%-39.75M | -21.49%-33.23M | -36.54%-27.35M | -23.04%-20.03M | -14.32%-16.28M | -13.57%-14.24M | -38.99%-12.54M | 3.89%-9.02M | -17.19%-9.39M |
| Payments to suppliers for goods and services | -11.82%-44.45M | -19.62%-39.75M | -21.49%-33.23M | -36.54%-27.35M | -23.04%-20.03M | -14.32%-16.28M | -13.57%-14.24M | -38.99%-12.54M | 3.89%-9.02M | -17.19%-9.39M |
| Direct interest received | -2.39%7.45M | 179.89%7.63M | 995.24%2.73M | -36.31%249K | -38.59%390.97K | 44.39%636.63K | 51.74%440.92K | 24.34%290.57K | 39.46%233.68K | -52.66%167.56K |
| Direct tax refund paid | -2.09%-15.73M | -105.83%-15.4M | -2,186.50%-7.48M | 350.14%358.69K | -81.18%79.68K | 1,100.16%423.37K | -80.81%35.28K | -4.75%183.84K | -63.88%193.01K | -8.06%534.3K |
| Operating cash flow | 10.91%41.1M | 0.38%37.05M | -7.42%36.91M | 107.00%39.87M | 35.76%19.26M | -23.12%14.19M | 57.83%18.46M | 17.91%11.69M | 296.88%9.92M | -11.20%-5.04M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -64.35%-47.72M | -2,725.60%-29.03M | -136.52%-1.03M | 49.15%-434.44K | 3.88%-854.33K | -245.02%-888.83K | -242.93%-257.62K | -11.33%-75.12K | 31.18%-67.48K | -816.62%-98.05K |
| Net PPE purchase and sale | 94.65%-298.57K | -442.68%-5.58M | -136.52%-1.03M | 49.15%-434.44K | 3.88%-854.33K | -245.02%-888.83K | -242.93%-257.62K | -11.33%-75.12K | 31.18%-67.48K | -816.62%-98.05K |
| Net investment purchase and sale | -102.14%-47.42M | ---23.46M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -64.35%-47.72M | -2,725.60%-29.03M | -136.52%-1.03M | 49.15%-434.44K | 3.88%-854.33K | -245.02%-888.83K | -242.93%-257.62K | -11.33%-75.12K | 31.18%-67.48K | -816.62%-98.05K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 17.73%-2.94M | -59.45%-3.57M | -48.97%-2.24M | -1.61%-1.5M | 0.40%-1.48M | -44.17%-1.49M | -1.03M | -98.99%85.08K | 3,666.67%8.39M | |
| Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | 74.83%-18.5K | ---73.51K | ---- | ---- | ---- |
| Net common stock issuance | 66.60%-251.91K | ---754.24K | ---- | ---- | ---- | ---- | ---- | ---- | -98.99%85.08K | 3,666.67%8.39M |
| Cash dividends paid | -1.37%-2.5M | -24.99%-2.47M | -60.00%-1.98M | 0.00%-1.24M | -0.92%-1.24M | -27.88%-1.22M | ---957.16K | ---- | ---- | ---- |
| Interest paid (cash flow from financing activities) | ---- | ---- | ---- | ---- | ---44.41K | ---- | ---- | ---- | ---- | ---- |
| Net other financing activities | 73.70%-182.7K | -31.71%-694.69K | 1.78%-527.44K | -34.06%-536.98K | 17.70%-400.56K | ---486.68K | ---- | ---- | ---- | --89.12K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 17.73%-2.94M | -59.45%-3.57M | -48.97%-2.24M | -1.61%-1.5M | 0.40%-1.48M | -44.17%-1.49M | ---1.03M | ---- | -98.99%85.08K | 3,666.67%8.39M |
| Net cash flow | ||||||||||
| Beginning cash position | 10.37%35.2M | -73.75%31.89M | 46.94%121.51M | 23.89%82.69M | 22.99%66.75M | 49.92%54.27M | 52.40%36.2M | 71.56%23.75M | 30.95%13.84M | -27.71%10.57M |
| Current changes in cash | -314.91%-9.56M | -86.78%4.45M | -11.31%33.64M | 124.09%37.93M | 43.29%16.93M | -31.19%11.81M | 47.77%17.17M | 16.95%11.62M | 205.36%9.93M | 175.35%3.25M |
| Effect of exchange rate changes | 308.63%2.38M | -168.71%-1.14M | 87.72%1.66M | 189.92%884.21K | -248.07%-983.32K | -26.42%664.08K | 9.00%902.48K | 3,174.37%827.93K | -241.53%-26.93K | -92.81%19.03K |
| End cash Position | -20.40%28.02M | -77.55%35.2M | 29.05%156.81M | 46.94%121.51M | 23.89%82.69M | 22.99%66.75M | 49.92%54.27M | 52.40%36.2M | 71.56%23.75M | 30.95%13.84M |
| Free cash from | 29.61%40.8M | -12.28%31.48M | -9.01%35.88M | 114.25%39.44M | 38.41%18.41M | -26.92%13.3M | 56.64%18.2M | 17.96%11.62M | 291.81%9.85M | -13.06%-5.13M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm